CGON - NASDAQ
CG Oncology, Inc. Common stock
$54.42
-0.85%CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
At a Glance
Live SnapshotCG Oncology, Inc. Common stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
CG Oncology, Inc. Common stock Cash Flow Statement
CGON • NASDAQ
| CG Oncology, Inc. Common stock Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||
-161M | -88M | -48.6M | -35.4M | -12.8M | |
1.4M | 32K | 17K | 15K | 10K | |
26.7M | 11.4M | 1.5M | 676K | 1.1M | |
-1.7M | -5M | -2.1M | 509K | 30K | |
2.3M | 2.9M | 3.4M | 4.4M | -2M | |
-132.3M | -78.7M | -45.7M | -29.8M | -13.7M | |
INVESTING ACTIVITIES | |||||
-134K | -234K | (0.0) | -14K | -97K | |
-22M | (0.0) | (0.0) | (0.0) | (0.0) | |
-1.1B | -1B | -517.6M | -55.3M | (0.0) | |
844.1M | 745.4M | 396.4M | 0.0 | 0.0 | |
-245.8M | -300.8M | -121.2M | -55.4M | -97K | |
FINANCING ACTIVITIES | |||||
153.6M | 629.5M | 0.0 | 166K | 245K | |
0.0 | -365K | -16.3M | 0.0 | 15.2M | |
0.0 | -825K | -1.3M | 0.0 | 0.0 | |
153.6M | 628.3M | 87M | 119.7M | 15.4M | |
CASH FLOW SUMMARY | |||||
-224.6M | 248.8M | -79.9M | 34.5M | 1.7M | |
257.1M | 8.3M | 88.1M | 53.6M | 51.9M | |
32.5M | 257.1M | 8.3M | 88.1M | 53.6M | |
-132.5M | -78.9M | -45.7M | -29.8M | -13.8M |
SEC Filings
CGON - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 26, 2026 | May 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 08, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | April 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 26, 2025 | November 22, 2025 | 2025 |
Related Guides
Continue your CGON research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.